Biophytis SA announces several amendments to the bond financing announced on August 5, 2025, in joint agreement with Hexagon Capital Fund.
MARCH 31, 2023
Other Press Releases
Read more
Biophytis announces the signing of a landmark agreement to create a Hong Kong-based joint venture, Biophytis Biopharmaceutical Holding Ltd, designed to accelerate the development and commercialization of BIO101 in sarcopenia…
Biophytis announces its participation in two leading healthcare and investment events in January 2026.
All resolutions presented by the Company have been adopted Biophytis announces the approval of all the resolutions presented by the Group and falling within the remit of the Ordinary and…
Biophytis reports its financial results for the first half of 2025 and provides an update on its strategic outlook. Stanislas Veillet, Chief Executive Officer of Biophytis, stated: “The first half…
BIOPHYTIS and a Consortium of Investors including RONGHUI RENHE Life Technology Join Forces to Finance and Launch First-Ever Phase 3 Trial in Sarcopenia Creation of a joint venture in Hong…
